SNSE vs. ADXN, TCRT, ITRM, DRRX, ALRN, FBRX, UBX, EYEN, XGN, and BFRG
Should you be buying Sensei Biotherapeutics stock or one of its competitors? The main competitors of Sensei Biotherapeutics include Addex Therapeutics (ADXN), Alaunos Therapeutics (TCRT), Iterum Therapeutics (ITRM), DURECT (DRRX), Aileron Therapeutics (ALRN), Forte Biosciences (FBRX), Unity Biotechnology (UBX), Eyenovia (EYEN), Exagen (XGN), and Bullfrog AI (BFRG). These companies are all part of the "medical" sector.
Sensei Biotherapeutics (NASDAQ:SNSE) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
In the previous week, Addex Therapeutics had 3 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 4 mentions for Addex Therapeutics and 1 mentions for Sensei Biotherapeutics. Addex Therapeutics' average media sentiment score of 0.33 beat Sensei Biotherapeutics' score of 0.00 indicating that Addex Therapeutics is being referred to more favorably in the news media.
Addex Therapeutics has higher revenue and earnings than Sensei Biotherapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 25.5% of Sensei Biotherapeutics shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Sensei Biotherapeutics has a net margin of 0.00% compared to Addex Therapeutics' net margin of -550.78%. Sensei Biotherapeutics' return on equity of -44.01% beat Addex Therapeutics' return on equity.
Sensei Biotherapeutics has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.
Sensei Biotherapeutics presently has a consensus target price of $4.00, suggesting a potential upside of 310.34%. Given Sensei Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Sensei Biotherapeutics is more favorable than Addex Therapeutics.
Sensei Biotherapeutics received 10 more outperform votes than Addex Therapeutics when rated by MarketBeat users. Likewise, 75.86% of users gave Sensei Biotherapeutics an outperform vote while only 46.15% of users gave Addex Therapeutics an outperform vote.
Summary
Sensei Biotherapeutics beats Addex Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Sensei Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensei Biotherapeutics Competitors List
Related Companies and Tools
